» Articles » PMID: 20068163

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

Overview
Journal Cancer Res
Specialty Oncology
Date 2010 Jan 14
PMID 20068163
Citations 2631
Authors
Affiliations
Soon will be listed here.
Abstract

This brief perspective article focuses on the most common errors and pitfalls, as well as the do's and don'ts in drug combination studies, in terms of experimental design, data acquisition, data interpretation, and computerized simulation. The Chou-Talalay method for drug combination is based on the median-effect equation, derived from the mass-action law principle, which is the unified theory that provides the common link between single entity and multiple entities, and first order and higher order dynamics. This general equation encompasses the Michaelis-Menten, Hill, Henderson-Hasselbalch, and Scatchard equations in biochemistry and biophysics. The resulting combination index (CI) theorem of Chou-Talalay offers quantitative definition for additive effect (CI = 1), synergism (CI < 1), and antagonism (CI > 1) in drug combinations. This theory also provides algorithms for automated computer simulation for synergism and/or antagonism at any effect and dose level, as shown in the CI plot and isobologram, respectively.

Citing Articles

Unveiling radiobiological traits and therapeutic responses of BRAF-mutant colorectal cancer via patient-derived organoids.

Mu P, Mo S, He X, Zhang H, Lv T, Xu R J Exp Clin Cancer Res. 2025; 44(1):92.

PMID: 40069844 PMC: 11895145. DOI: 10.1186/s13046-025-03349-z.


Dual acting oxaliplatin (IV) prodrug loaded albumin nanoparticles for safer synergistic anticancer action against triple negative breast cancer.

Abhang K, Dighe S, Katari O, Yadav V, Jain S Drug Deliv Transl Res. 2025; .

PMID: 40069528 DOI: 10.1007/s13346-025-01833-9.


Dual Modulation of Canonical and Non-canonical TGF-β/ROS/Erk1/2 Pathways: Synergistic Activation of Nrf-2 and Antioxidant Enzymes (SOD1, GPx, HO-1) by Quercetin Loaded in Solid Lipid Nanoparticles and Curcumin in Atherosclerosis Therapy.

Shamsi M, Mohammadzadeh G, Hatami M, Roshanazadeh M, Noor-Behbahani M, Rashidi M Iran J Pharm Res. 2025; 23(1):e151428.

PMID: 40066126 PMC: 11892753. DOI: 10.5812/ijpr-151428.


Malleatin A and B: New Premyrsine-Type Diterpenes from with Cytotoxic Effects Against A2780 Wild and A2780 R-CIS Ovarian Cancer Cell Lines in Mono or Combination Treatment with Cisplatin.

Zolfaghari B, Akbari F, Esmaeili S, Aghaei M, Mosaffa F, Ghorbanhosseini S Iran J Pharm Res. 2025; 23(1):e147396.

PMID: 40066114 PMC: 11892754. DOI: 10.5812/ijpr-147396.


Beta-lactam combination treatment overcomes rifampicin resistance in Mycobacterium tuberculosis.

Quan D, Wang T, Martinez E, Kim H, Sintchenko V, Britton W Eur J Clin Microbiol Infect Dis. 2025; .

PMID: 40048098 DOI: 10.1007/s10096-025-05062-3.